BRIEF published on 12/05/2024 at 13:05, 1 year 9 months ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
PRESS RELEASE published on 12/05/2024 at 13:00, 1 year 9 months ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 1 year 9 months ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
PRESS RELEASE published on 11/27/2024 at 23:05, 1 year 9 months ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 year 10 months ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 1 year 10 months ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 1 year 10 months ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 11/13/2024 at 00:23, 1 year 10 months ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 10/07/2024 at 13:05, 1 year 11 months ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 1 year 11 months ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
Published on 09/19/2026 at 00:55, 4 hours 11 minutes ago Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 5 hours 16 minutes ago Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 7 hours 6 minutes ago Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 8 hours 31 minutes ago Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 14 hours 36 minutes ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/18/2026 at 18:44, 10 hours 22 minutes ago EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:13, 10 hours 53 minutes ago Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:09, 10 hours 56 minutes ago Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:07, 10 hours 59 minutes ago Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:34, 10 hours 32 minutes ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 11 hours 21 minutes ago Press Release_Carrefour Bond_September 2026
Published on 09/17/2026 at 17:40, 1 day 11 hours ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
